What began as a tribute to the late Deanne Reeve has grown into a multimillion-dollar movement championing better health care for women across Nova Scotia.
With donations continuing to pour in following the sold-out Orchid Gala presented by TD, the Orchid Women's Health Initiative (OWHI) is celebrating $1.3 million net raised in 2026 in support of the QEII Foundation. More than 300 guests gathered at Steele Wheels Motor Museum on October 24 for an unforgettable evening of philanthropy, featuring a surprise performance by Blue Rodeo's Jim Cuddy and Nova Scotia's own Adam Baldwin.
This year's Orchid Gala proceeds will unlock more personalized cancer treatment options for patients facing gynecologic cancers. The unprecedented success of the 2026 event brings the OWHI's cumulative fundraising impact to more than $4.6 million raised for women’s health since 2023.
Behind this extraordinary milestone are nine passionate women — Jennifer Auld, Charlene Corkum, Lisa Gallivan, Alana Gammon, Julie Metlege, Sheri Morgan, Vicki Rafuse, Liz Rigney and Allyson Watson — united by a determination to honour the memory of Deanne, who passed away in 2020 following a late diagnosis of cervical cancer.
Their mission is clear: champion better access, introduce new treatment options and help more patients receive the exceptional care they deserve.
FROM ADVANCED SURGERY RECRUITING TWO SURGEONS TO MORE PERSONALIZED CANCER TREATMENT
For the second consecutive year, the OWHI's signature Orchid Gala event has supported the QEII Foundation, helping bring leading-edge advancements to Atlantic Canada's largest and most specialized hospital: the QEII Health Sciences Centre.
This year's $1.3 million will support comprehensive genomic profiling (CGP) and homologous recombination deficiency (HRD) testing at the QEII — powerful precision oncology tools that can help change the course of an individual patient's cancer treatment.
Using a single tumour sample, CGP can analyze hundreds of genes at once, uncovering the unique characteristics of a person's cancer and providing valuable insights into which treatments may be most effective. For someone facing endometrial cancer, these insights could mean avoiding chemotherapy that is unlikely to benefit them — and the significant side effects that come with it. For a patient diagnosed with ovarian cancer, HRD testing could help identify highly targeted therapies that may be the most effective against their cancer.
Bringing these advanced testing capabilities to the QEII is equally significant. With more comprehensive testing performed right here in Nova Scotia, cancer care teams could receive critical results sooner, helping reduce the time patients spend waiting for answers and guiding important decisions about their next steps in treatment.
It's an investment in a future where cancer care is increasingly tailored to each individual — giving more women access to the right treatments based on the unique biology of their disease.
While this year's Orchid Gala will advance how cancer treatments are selected, last year's event is already changing how cancer surgery is performed. In 2025, Orchid Gala supporters raised a record-breaking $1.9 million net to help fund the QEII's da Vinci Xi surgical robot.
Now in use by QEII cancer care teams, this groundbreaking technology is helping double access to robot-assisted gynecologic oncology procedures — allowing more eligible patients to benefit from less invasive surgery, fewer complications and faster recoveries.
But the impact reaches far beyond the operating room. The availability of advanced surgical robotics has also helped recruit two new gynecologic oncology surgeons to the QEII — Dr. Jacob McGee from Ontario and Dr. Chuck Dietrich from Kentucky — expanding the specialized expertise available to patients in our region.
For Dr. Dietrich, who joined the QEII from the University of Kentucky, access to the da Vinci Xi was an important factor in his decision to practice here.
“The da Vinci Xi is a really powerful tool, and its application in gynecologic oncology is amazing,” says Dr. Dietrich.
It's a prime example of how philanthropy is not only advancing the care available at the QEII, but also attracting the highly skilled specialists who deliver it.
“For those facing gynecologic cancers, having access to the most advanced technology and treatment options can make an enormous difference,” says Dr. Stephanie Scott, Division Head of Gynecologic Oncology at the QEII.
"We're already seeing the impact of last year's Orchid Gala through the da Vinci Xi surgical robot, and this year's investment in comprehensive genomic profiling and HRD testing represents another exciting advancement. These are meaningful improvements in the care we can provide and the surgeons we can attract, which is why we're so grateful to the Orchid Women's Health Initiative and everyone who continues to support our patients," says Dr. Scott.
TURNING PASSION INTO PROGRESS
At a time when women's healthcare access and wait times remain top of mind across Nova Scotia, the OWHI is demonstrating what can happen when community leaders come together with healthcare teams and hospital foundations around a shared vision for better care.
Their commitment goes beyond fundraising. By mobilizing philanthropic support around some of the most pressing priorities in women's health, they're helping turn opportunities for improvement into tangible progress for patients and families.
“What's so extraordinary about the Orchid Women's Health Initiative is that these women aren't simply imagining a better future for health care — they're helping make it possible,” says Susan Mullin, president and CEO of the QEII Foundation. “They're challenging the status quo, setting ambitious goals and inspiring an entire community to make women's health a priority. What they've accomplished in just four years speaks volumes about their leadership and determination. We're continually inspired by these women, and it's an absolute privilege to work alongside them. We couldn't be more grateful for their partnership and the incredible impact they're helping us achieve for patients at the QEII.”
With plans underway for the 2027 Orchid Gala, the OWHI is setting its sights on another transformative investment at the QEII — one that will help build specialized expertise, attract and retain physicians, and expand access to gynecologic cancer care across Nova Scotia. For the hundreds of donors, business leaders and community champions who have been part of this journey, there is much to celebrate and even more to look forward to.
Four years. More than $4.6 million raised. And they're just getting started.